Analysts Issue Forecasts for CADL Q4 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Analysts at Brookline Capital Management issued their Q4 2025 earnings per share (EPS) estimates for shares of Candel Therapeutics in a research note issued on Sunday, December 7th. Brookline Capital Management analyst K. Dolliver expects that the company will post earnings per share of ($0.22) for the quarter. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.47) per share.

Several other equities analysts also recently commented on CADL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Candel Therapeutics in a research note on Monday, September 29th. Citigroup reduced their price target on Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, November 14th. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Finally, Bank of America downgraded Candel Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $13.00 to $7.00 in a research report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.33.

Candel Therapeutics Trading Up 2.5%

CADL stock opened at $5.80 on Wednesday. Candel Therapeutics has a twelve month low of $4.25 and a twelve month high of $14.60. The stock has a market capitalization of $318.42 million, a price-to-earnings ratio of -10.18 and a beta of -0.92. The company has a quick ratio of 8.25, a current ratio of 8.25 and a debt-to-equity ratio of 0.01. The firm’s fifty day simple moving average is $5.23 and its two-hundred day simple moving average is $5.50.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04).

Institutional Investors Weigh In On Candel Therapeutics

Large investors have recently modified their holdings of the business. Halter Ferguson Financial Inc. boosted its holdings in shares of Candel Therapeutics by 12.0% in the 2nd quarter. Halter Ferguson Financial Inc. now owns 776,516 shares of the company’s stock valued at $3,929,000 after acquiring an additional 83,363 shares during the last quarter. Acorn Capital Advisors LLC boosted its holdings in Candel Therapeutics by 11.0% in the first quarter. Acorn Capital Advisors LLC now owns 2,152,252 shares of the company’s stock valued at $12,160,000 after purchasing an additional 212,608 shares during the last quarter. Nuveen LLC acquired a new stake in Candel Therapeutics during the 1st quarter worth about $442,000. Tanager Wealth Management LLP purchased a new position in shares of Candel Therapeutics during the 2nd quarter valued at about $995,000. Finally, Janney Montgomery Scott LLC raised its stake in shares of Candel Therapeutics by 29.4% during the 2nd quarter. Janney Montgomery Scott LLC now owns 27,290 shares of the company’s stock valued at $138,000 after buying an additional 6,200 shares during the last quarter. Institutional investors own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.